Caplin M E, Buscombe J R, Hilson A J, Jones A L, Watkinson A F, Burroughs A K
Neuroendocrine Tumour Group and Clinic, Royal Free Hospital, London, UK.
Lancet. 1998 Sep 5;352(9130):799-805. doi: 10.1016/S0140-6736(98)02286-7.
Carcinoid tumours are often indolent asymptomatic tumours. However, a small but significant proportion are malignant and difficult to manage. Multiple endocrine neoplasia type 1 (MEN-1) may be associated with carcinoid tumours and should therefore be considered in the investigation of these patients. This review puts into context the use of newer imaging modalities, including octreotide scintigraphy. The therapeutic treatment options are discussed, including the use of octreotide, the role of receptor-targeted therapy, hepatic-artery embolisation, and the arguments against chemotherapy. We review the need for careful patient selection when considering curative and palliative surgery, including liver transplantation. We conclude that there are now better diagnostic tools and therapeutic options available for those patients with malignant carcinoid tumours, and that these patients are best managed by a multidisciplinary approach. Earlier detection and treatment of these tumours should lead to improved quality of life and survival, which, ideally, should be assessed in formal trials.
类癌肿瘤通常是生长缓慢的无症状肿瘤。然而,有一小部分但数量可观的肿瘤是恶性的,且难以处理。1型多发性内分泌肿瘤(MEN - 1)可能与类癌肿瘤相关,因此在对这些患者进行调查时应予以考虑。本综述阐述了包括奥曲肽闪烁扫描术在内的新型成像方式的应用情况。文中讨论了治疗选择,包括奥曲肽的使用、受体靶向治疗的作用、肝动脉栓塞以及反对化疗的观点。我们回顾了在考虑根治性和姑息性手术(包括肝移植)时仔细选择患者的必要性。我们得出结论,对于那些患有恶性类癌肿瘤的患者,现在有了更好的诊断工具和治疗选择,并且这些患者最好通过多学科方法进行管理。对这些肿瘤的早期检测和治疗应能改善生活质量和生存率,理想情况下,这应该在正式试验中进行评估。